GSK-208136/006 (MeMuRu-OKA-006)

A phase II, open, randomized, multicentre study evaluating in healthy children 12-24 months of age, the safety and immunogenicity of GlaxoSmithKline Biologicals' combined Measles-Mumps-Rubella-Varicella vaccine (MeMuRu-OKA), compared to GlaxoSmithKline Biologicals' Varicella vaccine
Combined Measles, Mumps, Rubella, Varicella Vaccine
208136/006 (MeMuRu-OKA-006)
Measles; Mumps; Rubella; Varicella
Phase 2
An annotated case report form is not available for this study. A blank case report form will be provided. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
September 2015